Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives.

Medical review (Berlin, Germany) Pub Date : 2023-01-16 eCollection Date: 2022-12-01 DOI:10.1515/mr-2022-0033
Longchao Liu, Jiahui Chen
{"title":"Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives.","authors":"Longchao Liu,&nbsp;Jiahui Chen","doi":"10.1515/mr-2022-0033","DOIUrl":null,"url":null,"abstract":"<p><p>Antibodies, as one of the most important components of host adaptive immune system, play an important role in defense of infectious disease, immune surveillance, and autoimmune disease. Due to the development of recombinant antibody technology, antibody therapeutics become the largest and rapidly expanding drug to provide major health benefits to patients, especially for the treatment of cancer patients. Many antibody-based therapeutic strategies have been developed including monoclonal antibodies, antibody-drug conjugates, bispecific and trispecific antibodies and pro-antibodies with promising results from both clinical and pre-clinical trials. However, the response rate and side-effect still vary between patients with undefined mechanisms. Here, we summarized the current and future perspectives of antibody-based cancer immunotherapeutic strategies for designing next-generation drugs.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"2 6","pages":"555-569"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/31/76/mr-2-6-mr-2022-0033.PMC10471122.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical review (Berlin, Germany)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/mr-2022-0033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/12/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Antibodies, as one of the most important components of host adaptive immune system, play an important role in defense of infectious disease, immune surveillance, and autoimmune disease. Due to the development of recombinant antibody technology, antibody therapeutics become the largest and rapidly expanding drug to provide major health benefits to patients, especially for the treatment of cancer patients. Many antibody-based therapeutic strategies have been developed including monoclonal antibodies, antibody-drug conjugates, bispecific and trispecific antibodies and pro-antibodies with promising results from both clinical and pre-clinical trials. However, the response rate and side-effect still vary between patients with undefined mechanisms. Here, we summarized the current and future perspectives of antibody-based cancer immunotherapeutic strategies for designing next-generation drugs.

Abstract Image

用于精确癌症免疫疗法的治疗性抗体:当前和未来前景。
抗体作为宿主适应性免疫系统的重要组成部分,在传染病防御、免疫监测和自身免疫性疾病中发挥着重要作用。由于重组抗体技术的发展,抗体疗法成为最大且快速扩张的药物,为患者提供重大的健康益处,尤其是用于治疗癌症患者。已经开发了许多基于抗体的治疗策略,包括单克隆抗体、抗体-药物偶联物、双特异性和三特异性抗体以及前抗体,临床和临床前试验都取得了有希望的结果。然而,不同机制的患者的反应率和副作用仍然不同。在此,我们总结了基于抗体的癌症免疫治疗策略的当前和未来前景,以设计下一代药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.30
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信